Oral small molecule GLP-1 receptor agonist
Vct220 po 160mg qd
VCT220_PO_160MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.29 (0.00 to 8.83) | 0.72 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.89 (0.06 to 9.57) | 0.66 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 7.39 (3.15 to 19.57) | 0.19 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 5.25 (1.98 to 15.88) | 0.42 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.76 (0.98 to 8.41) | 0.35 |